Pharma BD Deal Intelligence
Sanofi S.A. / Vicebio Ltd.
2025 · Acquisition/Merger · $1.6B · Complete
Sanofi agreed to acquire London-based Vicebio Ltd., a privately held vaccine biotech, for $1.15 billion upfront plus up to $450 million in development and regulatory milestone payments. The deal adds Vicebio's proprietary "Molecular Clamp" antigen-stabilization technology and an early-stage combination vaccine candidate targeting RSV and human metapneumovirus, extending Sanofi's respiratory vaccine pipeline beyond mRNA. The transaction was expected to close in Q4 2025 subject to regulatory approvals and was not expected to materially affect Sanofi's 2025 financial guidance.
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2030 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jul 22, 2025
- Deal value $1.6B
- Deal type Acquisition/Merger
- Therapeutic area Vaccines, Infectious Disease
- Indications Respiratory syncytial virus (RSV), Human metapneumovirus (hMPV)
- Key assets RSV/hMPV combination vaccine candidate
- Mechanism Molecular Clamp stabilized non-mRNA antigen vaccine
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2025 deals · Vaccines deals